Retatrutide vs Amycretin

Retatrutide vs Amycretin: Overview

Retatrutide and amycretin are two investigational compounds that represent distinct multi-receptor strategies in metabolic disease research. Retatrutide is a triple hormone receptor agonist targeting GLP-1, GIP, and glucagon receptors, while amycretin is a novel unimolecular GLP-1 and amylin receptor agonist. The comparison of retatrutide vs amycretin is particularly compelling because both agents engage multiple metabolic pathways but through fundamentally different receptor combinations, offering researchers the opportunity to evaluate which hormonal axes yield the most favourable therapeutic profiles.

The investigation of amycretin vs retatrutide also reflects the evolving understanding that single-receptor approaches may not maximise metabolic benefit. While retatrutide incorporates glucagon receptor agonism to enhance energy expenditure and hepatic fat metabolism, amycretin combines incretin signalling with amylin-mediated satiety pathways. These distinct strategies provide complementary insights into the optimal design of multi-receptor therapeutics for metabolic disease.

Both compounds are in relatively early stages of clinical development, with retatrutide having completed phase 2 trials and amycretin having initial phase 1b/2a data. This comparison examines the available preclinical and clinical evidence to provide a research-focused analysis of these emerging agents.

Mechanism of Action

Retatrutide simultaneously activates three receptor systems: GLP-1, GIP, and glucagon receptors. The GLP-1 component provides appetite suppression, glucose-dependent insulin secretion, and delayed gastric emptying. GIP receptor agonism may enhance insulin sensitivity and modulate adipose tissue function. Glucagon receptor activation promotes hepatic energy expenditure, fatty acid oxidation, and thermogenesis. Retatrutide represents the broadest multi-agonist approach currently in clinical development, engaging both incretin and glucagon pathways in a single molecule (Son et al., 2026; Goldney et al., 2025).

Amycretin is a first-in-class unimolecular agonist that combines GLP-1 receptor agonism with amylin receptor agonism in a single peptide. The GLP-1 component provides similar incretin-mediated effects as in retatrutide — appetite reduction, glycaemic improvement, and gastric motility modulation. The amylin receptor component adds a complementary satiety signal that acts through brainstem pathways, mimicking the physiological hormone co-secreted with insulin from pancreatic beta cells. This represents a distinct neurohormonal approach to appetite regulation compared to the metabolic enhancement provided by glucagon receptor agonism (Dahl et al., 2025; Gasiorek et al., 2025).

The mechanistic distinction between retatrutide vs amycretin centres on their non-GLP-1 components: retatrutide adds GIP and glucagon receptor activity to drive energy expenditure and metabolic rate, while amycretin adds amylin receptor activity to enhance central satiety signalling. These approaches theoretically complement the shared GLP-1 component through different downstream mechanisms — peripheral energy expenditure versus central appetite regulation.

Clinical Evidence

Retatrutide has been evaluated in a comprehensive phase 2 clinical trial programme. The pivotal phase 2 trial in adults with obesity demonstrated dose-dependent weight reductions, with the highest dose achieving approximately 24.2% mean body weight loss over 48 weeks — one of the largest reductions observed with any pharmacological agent (Jastreboff et al., 2023). Additional phase 2 data in type 2 diabetes and metabolic dysfunction-associated steatotic liver disease have further characterised the compound’s metabolic effects (Sanyal et al., 2024; Kanu et al., 2025).

Amycretin’s clinical evidence is more limited, reflecting its earlier stage of development. The first-in-human phase 1 study established the safety, tolerability, pharmacokinetics, and pharmacodynamics of amycretin in healthy participants (Gasiorek et al., 2025). A subsequent phase 1b/2a randomised controlled study evaluated amycretin administered subcutaneously and demonstrated promising weight reduction in a short-duration trial, with weight loss data suggesting substantial efficacy potential (Dahl et al., 2025). However, the limited sample sizes, shorter treatment durations, and early-phase design of amycretin trials make definitive efficacy comparisons with retatrutide premature.

Reviews of emerging pharmacotherapies have positioned both retatrutide and amycretin among the most closely watched investigational agents in the metabolic disease pipeline (Kokkorakis et al., 2025; Bailey et al., 2025). Cross-compound comparisons are currently limited to qualitative assessments given the different stages of clinical development.

Efficacy Comparison

Direct efficacy comparisons between amycretin vs retatrutide are not possible at this stage due to the significant differences in available clinical data. Retatrutide’s phase 2 data in a large obesity trial demonstrated approximately 24.2% mean weight loss over 48 weeks, representing mature phase 2 evidence. Amycretin’s phase 1b/2a data, while showing promising weight reduction signals, come from smaller, shorter-duration studies that are not designed for definitive efficacy determination.

Early reports from amycretin’s phase 1b/2a programme suggested weight reductions that appeared substantial relative to the short treatment duration and early dose-finding context. If these signals are confirmed in larger, longer-duration trials, amycretin’s dual GLP-1/amylin approach could potentially demonstrate competitive weight reduction efficacy. However, until phase 2 or phase 3 data of comparable scope to retatrutide’s trials are available, efficacy comparisons remain speculative.

Both compounds are expected to influence glycaemic parameters given their GLP-1 receptor agonist components. Retatrutide’s additional GIP and glucagon receptor activity may provide broader metabolic effects including hepatic fat reduction and enhanced energy expenditure. Amycretin’s amylin component may particularly influence postprandial glucose excursions and food intake behaviour through distinct central nervous system pathways.

Safety and Tolerability

Retatrutide’s safety profile from phase 2 trials shows predominantly gastrointestinal adverse events including nausea, diarrhoea, vomiting, and decreased appetite, consistent with GLP-1 receptor agonist pharmacology. The glucagon receptor component introduces additional monitoring considerations for hepatic function and glucose homeostasis, though clinical data have not revealed unexpected safety signals at therapeutic doses. Heart rate increases have been observed, consistent with the GLP-1 receptor agonist class.

Amycretin’s safety data from phase 1 and phase 1b/2a studies have similarly shown gastrointestinal adverse events as the most common findings. The amylin receptor component does not appear to introduce markedly different safety concerns compared to GLP-1 receptor agonism alone, though the limited sample sizes and short treatment durations in early-phase studies restrict the comprehensiveness of safety characterisation (Dahl et al., 2025; Gasiorek et al., 2025). Native amylin in high concentrations is associated with amyloid formation in vitro, but engineered amylin analogues, including the component of amycretin, are designed to minimise this property.

A broader assessment of incretin co-agonist safety has suggested that multi-receptor compounds generally maintain safety profiles consistent with GLP-1 receptor agonists, with gastrointestinal events being the primary tolerability concern across the class (Bhat et al., 2025). Both retatrutide and amycretin will require longer-term safety data from larger clinical programmes to comprehensively characterise their risk profiles.

Pharmacokinetics

Retatrutide is administered as a once-weekly subcutaneous injection. The peptide has been engineered with structural modifications to extend its half-life and balance activity across three receptor targets. Pharmacokinetic data from clinical studies demonstrate exposure consistent with once-weekly dosing, with steady-state concentrations achieved within several weeks of repeated administration.

Amycretin is administered subcutaneously, with early-phase studies evaluating various dosing intervals. As a unimolecular dual agonist containing both GLP-1 and amylin receptor-activating components within a single peptide chain, amycretin’s pharmacokinetic properties reflect the engineered modifications required to achieve adequate half-life and balanced receptor engagement. The first-in-human pharmacokinetic characterisation established dose-proportional exposure and supported the feasibility of intermittent subcutaneous dosing (Gasiorek et al., 2025).

Both compounds are subcutaneous injectables requiring peptide-compatible formulation and storage conditions. Neither is available as an oral formulation. The pharmacokinetic comparison between retatrutide vs amycretin will become more informative as amycretin’s dosing regimen is optimised through later-phase clinical development and as more detailed pharmacokinetic comparisons become available.

Current Research Status

Retatrutide is in phase 3 clinical development through the TRIUMPH registrational programme, which evaluates the compound across obesity, obstructive sleep apnoea, and knee osteoarthritis indications (Giblin et al., 2026). Retatrutide is not yet approved in any jurisdiction but is widely considered one of the most advanced triple agonists in development. Results from TRIUMPH will determine whether the exceptional phase 2 weight loss data translate into registrational-quality phase 3 outcomes.

Amycretin is in early clinical development, with phase 1 and phase 1b/2a data published. As a first-in-class GLP-1 and amylin receptor dual agonist, amycretin occupies a unique mechanistic position. Phase 2 and phase 3 programmes are anticipated but have not yet reported results. The compound’s development timeline is earlier than retatrutide’s, and its regulatory path will depend on the outcomes of larger-scale clinical evaluations.

The competitive landscape between amycretin vs retatrutide will become clearer as both compounds advance through clinical development. The different receptor combinations they employ — GLP-1/GIP/glucagon for retatrutide and GLP-1/amylin for amycretin — may ultimately serve different research and therapeutic niches, or one approach may emerge as clearly superior based on efficacy and safety data from phase 3 programmes.

Summary

Retatrutide and amycretin are both multi-receptor agonists but target fundamentally different pathway combinations. Retatrutide activates GLP-1, GIP, and glucagon receptors with phase 2 data showing approximately 24% weight loss, while amycretin is a first-in-class GLP-1 and amylin receptor agonist with promising early-phase data. The key differences include receptor targets (triple incretin/glucagon vs dual incretin/amylin), development stage (phase 3 vs early clinical), and mechanistic emphasis (energy expenditure enhancement vs central satiety augmentation). Both compounds demonstrate the field’s shift toward multi-receptor strategies, and the comparison of retatrutide vs amycretin will be increasingly informative as amycretin progresses through clinical development.

References

• Jastreboff AM et al. (2023). Triple-Hormone-Receptor Agonist Retatrutide for Obesity – A Phase 2 Trial. The New England Journal of Medicine. PMID: 37366315
• Dahl K et al. (2025). Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study. The Lancet. PMID: 40550231
• Gasiorek A et al. (2025). Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1 study. The Lancet. PMID: 40550229
• Son JW et al. (2026). Novel GLP-1-based Medications for Type 2 Diabetes and Obesity. Endocrine Reviews. PMID: 41054801
• Sanyal AJ et al. (2024). Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nature Medicine. PMID: 38858523
• Goldney J et al. (2025). Triple Agonism Based Therapies for Obesity. Current Cardiovascular Risk Reports. PMID: 40741227
• Giblin K et al. (2026). Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH programme. Diabetes, Obesity & Metabolism. PMID: 41090431
• Bailey CJ et al. (2025). Multifunctional incretin peptides in therapies for type 2 diabetes, obesity and associated co-morbidities. Peptides. PMID: 40081498
• Kokkorakis M et al. (2025). Emerging pharmacotherapies for obesity: A systematic review. Pharmacological Reviews. PMID: 39952695
• Bhat S et al. (2025). Efficacy and safety of incretin co-agonists: Transformative advances in cardiometabolic healthcare. World Journal of Cardiology. PMID: 40949933
• Kanu C et al. (2025). Appetite, eating attitudes, and eating behaviours during treatment with retatrutide in adults with type 2 diabetes. Diabetes, Obesity & Metabolism. PMID: 40916752